Skip to content

Author

Diego Centonze

We have 5 of 33 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Optimizing the Use of Anti-CD20 Agents in Multiple Sclerosis and Other Autoimmune Central Nervous System Disorders: A Narrative Review.

Anti-CD20 monoclonal antibodies have become central therapies for multiple sclerosis (MS) and other autoimmune disorders of the central nervous system, including neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and autoimmune encephalitis. These ag...

D. Ferraro, G. Abbadessa, Federica Azzolini et al. · 0 citations
Open access Aug 2026

CSF Cytokine Network Organization Predicts Progression Independent of Relapse and MRI Activity in Multiple Sclerosis

ABSTRACT Objective Progression independent of relapse activity is a major determinant of long‐term disability in multiple sclerosis, but its immunopathologic basis remains incompletely understood. We investigated whether relapse‐independent progression in radiologically stable relapsing–remitting multiple sclerosis is...

Antonio Bruno, M. Conti, Ettore Dolcetti et al. · 0 citations
Open access Oct 2026

Horizon Scanning of Multiple Sclerosis Expenditure in Italy (2025-2029): Updated Insights from the Oracle Model.

INTRODUCTION Multiple sclerosis (MS) is a chronic and progressively disabling neurological disease associated with a substantial clinical and socioeconomic burden. The introduction of an increasing number of new innovative therapies has further intensified concerns regarding the long-term sustainability for the Italian...

Diego Centonze, Massimiliano Calabrese, E. Cocco et al. · 0 citations
Open access Sep 2026

Lipid-Related Metabolic Dysregulation Affects Survival in Idiopathic Normal Pressure Hydrocephalus.

BACKGROUND Idiopathic normal pressure hydrocephalus (iNPH) is associated with increased mortality and vascular-metabolic comorbidity, but prognostic biomarkers are lacking. OBJECTIVES To assess the triglycerides/high-density lipoprotein cholesterol (TG/HDL-C) ratio, an insulin resistance (IR) marker, and its associat...

Jacopo Bissacco, D. Mascioli, C. Simonetta et al. · 0 citations
Open access Aug 2026

Instrumental, Neurophysiological, cognitive and Sleep InvestiGations into the High risk of neurodegeneraTion in Late Onset Epilepsy of Unknown aetiology: the INSIGHT-LOEU study.

This strategy could improve the early detection of cognitive decline, guide personalised management, and ultimately enhance quality of life, while contributing to the long-term sustainability of healthcare systems in an ageing population, focusing on LOEU as a model for dementia prevention.

G. Bergamo, M. Fernandes, S. Maio et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.